Abbott India vs Amgen

Abbott India Limited and Amgen Inc. are both prominent players in the pharmaceutical industry, but they differ in terms of size, market presence, and product offerings. Abbott India, a subsidiary of global healthcare giant Abbott Laboratories, specializes in a wide range of pharmaceutical products and medical devices. On the other hand, Amgen is a biotechnology company known for its innovative therapies in treating serious illnesses. Investors looking to diversify their portfolio may consider analyzing the performance and growth potential of both Abbott India and Amgen stocks.

Abbott India or Amgen?

When comparing Abbott India and Amgen, different investors may prioritize various metrics based on their investment strategies and goals. So, ask yourself what type of investor you are. This will guide you in determining which metrics are most important for your investment decision between Abbott India and Amgen.

Dividend Investors:

Dividend investors look for stable and growing income streams, using dividend metrics to assess potential investments. A company's dividend yield essentially measures the size of its dividend relative to the total market value of the company. Abbott India has a dividend yield of 1.41%, while Amgen has a dividend yield of 2.73%. Beyond the yield itself, considering the growth and sustainability of these dividends is also crucial. Abbott India reports a 5-year dividend growth of 96.10% year and a payout ratio of 0.00%. On the other hand, Amgen reports a 5-year dividend growth of 10.04% year and a payout ratio of 150.06%.

Value Investors:

Value investors focus on financial metrics to determine a stock's intrinsic value compared to its market value. The Price-to-Earnings (P/E) Ratio links stock price to a company's earnings per share, with Abbott India P/E ratio at 49.77 and Amgen's P/E ratio at 55.77. Another crucial valuation metric is the Price-to-Book (P/B) Ratio, which compares stock price with book value per share. Abbott India P/B ratio is 16.67 while Amgen's P/B ratio is 29.46.

Growth Investors:

Growth investors prioritize metrics indicative of a company's expansion potential. Focusing on top-line growth, Abbott India has seen a 5-year revenue growth of 0.59%, while Amgen's is 0.47%. Return on Equity (ROE) measures how effectively a company uses equity investment to generate earnings, with Abbott India's ROE at 37.82% and Amgen's ROE at 50.41%.

Retail Investors:

Retail investors often consider stock affordability and company familiarity. For example, day low prices are ₹28876.35 for Abbott India and $324.03 for Amgen. Over the past year, Abbott India's prices ranged from ₹22000.00 to ₹30521.00, with a yearly change of 38.73%. Amgen's prices fluctuated between $249.70 and $346.85, with a yearly change of 38.91%. Brand recognition also plays a role, as familiarity with a company can influence investment decisions.